Etanercept is a tumor necrosis factor antagonist that is used for the treatment of adult and juvenile from rheumatoid arthritis, it is also known as biopharmaceutical which is also used to treat autoimmune disorders. This biopharmaceutical is the United States FDA approved to treat psoriatic arthritis, juvenile idiopathic arthritis, rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis and many more diseases. Hence, rising accidents and obesity is growing in the industry.
- Increasing Prevalence of Rising Diseases such as Obesity and Accidents
- Rising Awareness about the Diseases such as Arthritis is also Driving the Market
- Growing Government Regulation Associated with Saftey and Efficiency of Etanercept can Hamper the market
Growing Healthcare Expenditure and Government Support is Boosting the Industry
Players Covered in the Study are:
Amgen (United States), Pfizer (United States), Takeda (Japan), Sanofi (France), GlaxoSmithKline (United Kingdom), Sandoz (Germany), Celltrion (South Korea), Dexa Medica (Indonesia), Bionovis (Brazil) and Momenta Pharmaceuticals (United States)
The Global Etanercept market is gaining huge competition due to involvement of Global companies that constantly invest in research & development to meet market expectation with new innovation.
List of players that can be included in the study on immediate basis are HanAll Biopharma (South Korea), MedImmune (United States) and Tsumura (Japan).